Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AZD2927
- Development stage
- Phase 2
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
AZD2927 is a small molecule investigational drug developed by AstraZeneca for the treatment of cardiac arrhythmias, specifically atrial fibrillation and atrial flutter. It acts as a selective blocker of the acetylcholine-regulated inwardly rectifying potassium current (IKACh) in human atrial myocytes (IC50=0.35 µM), with minimal off-target activity[1][5]. The drug targets the Kir3.1/Kir3.4 channel complex and is designed to prolong atrial refractoriness without affecting ventricular refractoriness or QT interval[5][7]. Preclinical studies demonstrated its efficacy in restoring sinus rhythm in animal models of atrial fibrillation[7]. Clinical development reached Phase II trials for arrhythmia indications but did not progress to approval[2][4][5].
- Other names
- CCR2 antagonist 3CCR-2 antagonist 3CCR 2 antagonist 31380100-86-6
02
Targets
KACh (G protein–activated inwardly rectifying potassium channel)
Beyond the preview
Go deeper on AZD2927.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AZD2927.